» Articles » PMID: 25136676

Vascular Calcification and Renal Bone Disorders

Overview
Publisher Wiley
Specialty Biology
Date 2014 Aug 20
PMID 25136676
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

At the early stage of chronic kidney disease (CKD), the systemic mineral metabolism and bone composition start to change. This alteration is known as chronic kidney disease-mineral bone disorder (CKD-MBD). It is well known that the bone turnover disorder is the most common complication of CKD-MBD. Besides, CKD patients usually suffer from vascular calcification (VC), which is highly associated with mortality. Many factors regulate the VC mechanism, which include imbalances in serum calcium and phosphate, systemic inflammation, RANK/RANKL/OPG triad, aldosterone, microRNAs, osteogenic transdifferentiation, and effects of vitamins. These factors have roles in both promoting and inhibiting VC. Patients with CKD usually have bone turnover problems. Patients with high bone turnover have increase of calcium and phosphate release from the bone. By contrast, when bone turnover is low, serum calcium and phosphate levels are frequently maintained at high levels because the reservoir functions of bone decrease. Both of these conditions will increase the possibility of VC. In addition, the calcified vessel may secrete FGF23 and Wnt inhibitors such as sclerostin, DKK-1, and secreted frizzled-related protein to prevent further VC. However, all of them may fight back the inhibition of bone formation resulting in fragile bone. There are several ways to treat VC depending on the bone turnover status of the individual. The main goals of therapy are to maintain normal bone turnover and protect against VC.

Citing Articles

Exploring the molecular interactions between nephrolithiasis and carotid atherosclerosis: asporin as a potential biomarker.

Hua Y, Zhou Z, Miao S, Wang Z, Song R, Meng X Urolithiasis. 2024; 52(1):169.

PMID: 39589536 DOI: 10.1007/s00240-024-01665-1.


Combinations of valvular calcification and serum alkaline phosphatase predict cardiovascular risk among end-stage kidney disease patients.

Chao C, Liao M, Wu C Int J Cardiol Heart Vasc. 2024; 54:101505.

PMID: 39290800 PMC: 11405837. DOI: 10.1016/j.ijcha.2024.101505.


Evaluating Osteoporosis in Chronic Kidney Disease: Both Bone Quantity and Quality Matter.

Lloret M, Fusaro M, Jorgensen H, Haarhaus M, Gifre L, Alfieri C J Clin Med. 2024; 13(4).

PMID: 38398323 PMC: 10889712. DOI: 10.3390/jcm13041010.


Association of aortic arch and aortic valve calcifications with cardiovascular risk in patients on maintenance hemodialysis.

Liao M, Chao C, Wu C Front Cardiovasc Med. 2022; 9:1053265.

PMID: 36561768 PMC: 9763299. DOI: 10.3389/fcvm.2022.1053265.


Coronary artery calcification in patients with advanced chronic kidney disease.

Xiang X, He J, Zhang W, He Q, Liu Y BMC Cardiovasc Disord. 2022; 22(1):453.

PMID: 36309659 PMC: 9618197. DOI: 10.1186/s12872-022-02879-0.


References
1.
Perwad F, Zhang M, Tenenhouse H, Portale A . Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007; 293(5):F1577-83. DOI: 10.1152/ajprenal.00463.2006. View

2.
Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, Lopez-Ongil S . RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res. 2009; 104(9):1041-8. DOI: 10.1161/CIRCRESAHA.108.189001. View

3.
Salem S, Bruck H, Bahlmann F, Peter M, Passlick-Deetjen J, Kretschmer A . Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol. 2011; 35(1):31-9. DOI: 10.1159/000334742. View

4.
Heiss A, DuChesne A, Denecke B, Grotzinger J, Yamamoto K, Renne T . Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem. 2003; 278(15):13333-41. DOI: 10.1074/jbc.M210868200. View

5.
Lomashvili K, Khawandi W, ONeill W . Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol. 2005; 16(8):2495-500. DOI: 10.1681/ASN.2004080694. View